LCCC 0406: ADDITION OF CELLCEPT TO GLEEVEC IN THE TREATMENT OF LEUKEMIA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是看看是否添加一种名为CellCept(也称为霉酚酸酯)的药物 格列卫(也称为甲磺酸伊马替尼或ST1571)用于慢性粒细胞白血病(CML)患者，将使一种名为bcr-abl的异常蛋白质水平下降，降幅超过格列卫本身。这项研究还将试图看看这样做是否会降低患者在缓解期或进展到更晚期和更危险的CML阶段时出现白血病复发等问题的可能性。最后，这项研究将检查另一种名为Lyn Kinase的蛋白质是否异常高，以及伊马替尼和霉酚酸酯联合使用是否会降低其水平。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to see if adding a medicine called CellCept (also called mycophenolate mofetil) to Gleevec (also called imatinib mesylate or ST1571) for patients with chronic myelogenous leukemia (CML) will make levels of an abnormal protein named BCR-ABL decrease to a greater extent than would happen with Gleevec by itself. The study will also try to see if doing so makes patients less likely to have problems from their leukemia like relapses if in remission or progression to more advanced and dangerous phases of CML. Finally, the study will examine whether another protein called LYN kinase is abnormally high and whether its levels go down with the combination of imatinib and mycophenolate.